Longeveron (LGVN) Other Non-Current Liabilities (2024 - 2025)
Longeveron's (LGVN) quarterly Other Non-Current Liabilities came in at $330000.0 in Q4 2025, up 24.53% year-on-year from $265000.0 in Q4 2024, and up 4.76% quarter-over-quarter from $315000.0 in Q3 2025.
Longeveron (LGVN) Other Non-Current Liabilities (2024 - 2025) Analysis & Trends
Longeveron's Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $330000.0 for Q4 2025.
- On a quarterly basis, Other Non-Current Liabilities rose 24.53% year-over-year to $330000.0 in Q4 2025; TTM through Dec 2025 was $330000.0, a 24.53% increase from a year earlier, with the FY2025 full-year figure at $330000.0, up 24.53% from the prior year.
- Other Non-Current Liabilities advanced to $330000.0 in Q4 2025 per LGVN's latest filing, from $315000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $330000.0 in Q4 2025 and bottomed at $66000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 330,000.00 |
| Sep 30, 2025 | 315,000.00 |
| Jun 30, 2025 | 308,000.00 |
| Mar 31, 2025 | 302,000.00 |
| Dec 31, 2024 | 265,000.00 |
| Sep 30, 2024 | 199,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 66,000.00 |